In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Kenta Biotech Ltd.

Latest From Kenta Biotech Ltd.

Deals Shaping The Medical Industry, June 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type –Acquisition, Alliance, or Financing.

BioPharmaceutical Medical Device

Anti-Infective Start-Ups See Opportunity In An Epidemiological Nightmare

Infectious disease researchers have been warning for decades of the growing numbers of drug-resistant bacteria, and a certain subset of investors and companies sees this epidemiological nightmare as an alluring business opportunity. We profile three emerging anti-infective drug developers in this issue: Arsanis Biosciences, ContraFect, and Fedora Pharmaceuticals.

BioPharmaceutical

Arsanis Biosciences GMBH

The classic approach to treating bacterial infection has been to “kill the bug.” But instead of seeking only to destroy bacteria, Arsanis Biosciences GMBH intends also to neutralize certain toxins, or virulence factors, released by bacteria. The start-up is preparing a mixture of monoclonal antibodies that it believes will help patients recover from severe infections by addressing the disease state at multiple levels. While the company intends for certain of its antibodies to make bacteria more visible to phagocytes, cells whose primary function is to chew up intruders, it expects other antibodies to mitigate inflammation that is a normal but ultimately unhelpful reaction to infection.

BioPharmaceutical

TetraPhase's Series C

Anti-infective developer TetraPhase Pharmaceuticals announced June 1 its $45 million Series C financing, with participation from a syndicate of new and existing backers. The financing is one of the richest of the year, just below the April $56 million Series C pulled in by Achaogen, which is also developing antibiotics for drug resistant diseases. And it far exceeds the average Series C financing of $19.77 million raised between January and May of this year.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register